HIV-associated neurocognitive disorder

Last updated
HIV-associated neurocognitive disorders
Other namesAIDS dementia complex (ADC), Brain AIDS, HIV dementia, HIV-associated dementia (HAD), HIV encephalopathy
Specialty Infectious disease, neurology

HIV-associated neurocognitive disorders (HAND) are neurological disorders associated with HIV infection and AIDS. It is a syndrome of progressive deterioration of memory, cognition, behavior, and motor function in HIV-infected individuals during the late stages of the disease, when immunodeficiency is severe. [1] HAND may include neurological disorders of various severity. HIV-associated neurocognitive disorders are associated with a metabolic encephalopathy induced by HIV infection and fueled by immune activation of macrophages and microglia. [2] These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. The essential features of HIV-associated dementia (HAD) are disabling cognitive impairment accompanied by motor dysfunction, speech problems and behavioral change. [3] Cognitive impairment is characterised by mental slowness, trouble with memory and poor concentration. Motor symptoms include a loss of fine motor control leading to clumsiness, poor balance and tremors. Behavioral changes may include apathy, lethargy and diminished emotional responses and spontaneity. Histopathologically, it is identified by the infiltration of monocytes and macrophages into the central nervous system (CNS), gliosis, pallor of myelin sheaths, abnormalities of dendritic processes and neuronal loss. [2] [4]

Contents

HAD typically occurs after years of HIV infection and is associated with low CD4+ T cell levels and high plasma viral loads. It is sometimes seen as the first sign of the onset of AIDS. Prevalence is between 10 and 24% in Western countries [5] and has only been seen in 1–2% of India-based infections. [6] [7] With the advent of highly active antiretroviral therapy (HAART), the incidence of HAD has declined in developed countries, although its prevalence is increasing. [8] [9] HAART may prevent or delay the onset of HAD in people with HIV infection, and may also improve mental function in people who already have HAD.

Dementia only exists when neurocognitive impairment in the patient is severe enough to interfere markedly with day-to-day function. That is, the patient is typically unable to work and may not be able to take care of themselves. Before this, the patient is said to have a mild neurocognitive disorder.

Presentation

Cognitive impairments associated with HIV occur in the domains of attention, memory, verbal fluency, and visuospatial construction. Specifically for memory, the lowered activity of the hippocampus changes the basis for memory encoding and affects mechanisms such as long-term potentiation. [10] Severity of impairment in different domains varies depending on whether or not a patient is being treated with HAART or monotherapy. [11] Studies have shown that patients exhibit cognitive deficits consistent with dysfunction of fronto-striatal circuits including associated parietal areas, the latter of which may account for observed deficits in visuospatial function. [12] [13] In addition to cognitive impairments, psychological dysfunction is also noted. For example, patients with HIV have higher rates of clinical depression and alexithymia, i.e., difficulty processing or recognizing one's own emotions. [12] Patients also have more difficulty recognizing facial emotions. [14]

Without combination antiretroviral therapy, cognitive impairments increase with successive stages of HIV. [15] HIV patients in early stages show mild difficulties in concentration and attention. [16] In advanced cases of HIV-associated dementia, speech delay, motor dysfunction, and impaired thought and behavior are observed. [16] Specifically, lower motor speeds were found to correlate with hypertrophy of the right putamen. [17]

The diagnosis of HIV-associated neurocognitive impairment is made using clinical criteria after considering and ruling out other possible causes. [16] The severity of neurocognitive impairment is associated with nadir CD4, suggesting that earlier treatment to prevent immunosuppression due to HIV may help prevent HIV-associated neurocognitive disorders. [15]

Pathophysiology

HIV-associated dementia (HAD) is not a true opportunistic infection; it is one of the few conditions caused directly by HIV itself. However, the cause of HAD can be difficult to discern because the central nervous system can be damaged by a number of other causes related to HIV infection: [ citation needed ]

Many researchers believe that HIV damages the vital brain cells, neurons, indirectly. According to one theory, HIV either infects or activates cells that protect the brain, known as macrophages and microglia. These cells then produce toxins that can set off a series of reactions that instruct neurons to self-destruct. The infected macrophages and microglia also appear to produce additional factors such as chemokines and cytokines that can affect neurons as well as other brain cells known as astrocytes. The affected astrocytes, which normally nurture and protect neurons, also may now end up harming neurons. Astrocytes produce neurotoxic proteins such as Tat, Nef and Rev. Tat is secreted and induces reactivity in astrocytes through increased GFAP expression. [18] HIV protein gp120 inhibits the stem cells in the brain from producing new nerve cells. [19] In the neuronal cells, the HIV gp120 induces mitochondrial-death proteins like caspases, which may influence the upregulation of the death receptor Fas leading to apoptosis. [20]

Direct effects of HIV

HIV enters the brain early on in the infection. [21] It is thought that HIV uses a "Trojan horse" mechanism to enter the brain. Normally, the blood–brain barrier (BBB) serves as a protective mechanism by preventing entry of foreign substances; disruption of the BBB by HIV contributes to the progression of infection. [22] The virus is able to enter the brain through infected cells that pass through the BBB to replace the immune cells surrounding the blood supply in the brain. When infected, immune cells are able to better migrate into tissues compared to uninfected cells. Infected microglia add to the production of the virus. This activation of the microglia may contribute to the process of neuropathogenesis that spreads the infection to nearby cells. [9] Other cells that can get infected include the astrocytes, which can trigger bystander cellular dysfunction and apoptosis, further compromising the blood–brain barrier. The toxicity spreads through a gap junction-dependent mechanism. [23]

Brain regions affected

HIV is associated with pathological changes in mainly subcortical and fronto-striatal areas of the brain, including the basal ganglia, deep white matter, and hippocampal regions. Neuroimaging studies of HIV patients indicate that significant volume reductions are apparent in the frontal white matter, whereas subcortically, hypertrophy is apparent in the basal ganglia, especially the putamen. [17] Moreover, the results of some studies suggest loss of brain volume in cortical and subcortical regions even in asymptomatic HIV patients and patients who were on stable treatment. [24] A recent longitudinal study of a small representative cohort of HIV-positive patients on stable medication regiments suggests that this cortical atrophy is progressive, and is in part related to nadir CD4. [25] Cerebral brain volume is associated with factors related to duration of the disease and CD4 nadir; patients with a longer history of chronic HIV and higher CD4 nadir loss present with greater cerebral atrophy. [24] CD4 lymphocyte counts have also been related to greater rates of brain tissue loss. [26] Current factors, such as plasma HIV RNA, have been found to be associated with brain volumes as well, especially with regards to basal ganglia volume [24] and total white matter. [27] Loss of cortical grey matter oligodendrocytes and neurons might also contribute to the symptomatology. [28]

Changes in the brain may be ongoing but asymptomatic, that is with minimal interference in functioning, making it difficult to diagnose HIV-associated neurocognitive disorders in the early stages. [29]

Diagnostic criteria

  1. Marked acquired impairment of at least two ability domains of cognitive function (e.g. memory, attention): typically, the impairment is in multiple domains, especially in learning, information processing and concentration/attention. The cognitive impairment is ascertained by medical history, mental status examination or neuropsychological testing.
  2. Cognitive impairments identified in 1 interfere markedly with day-to-day functioning.
  3. Cognitive impairments identified in 1 are present for at least one month.
  4. Cognitive impairments identified in 1 do not meet the criteria for delirium, or if delirium is present, dementia was diagnosed when delirium was not present.
  5. No evidence of another, pre-existing cause that could explain the dementia (e.g. another CNS infection, CNS neoplasm, cerebrovascular disease, pre-existing neurological disease, severe substance abuse compatible with CNS disorder. [30]

While the progression of dysfunction is variable, it is regarded as a serious complication and untreated can progress to a fatal outcome. Diagnosis is made by neurologists who carefully rule out alternative diagnoses. This routinely requires a careful neurological examination, brain scans (MRI or CT scan) and a lumbar puncture to evaluate the cerebrospinal fluid. No single test is available to confirm the diagnosis, but the constellation of history, laboratory findings and examination can reliably establish the diagnosis when performed by experienced clinicians. The amount of virus in the brain does not correlate well with the degree of dementia, suggesting that secondary mechanisms are also important in the manifestation of HAD.

HAD stage characteristics

Neuroimaging studies

A study by Melrose et al. (2008) examined the integrity of the fronto-striatal circuitry that underlies executive functioning in HIV. Participants in the study were diagnosed with HIV three months to sixteen years before the study. Ten out of eleven patients were on antiretroviral medication and none scored within the demented range on the HIV Dementia Scale. It was found that HIV+ patients showed less activity within the ventral prefrontal cortex (PFC) and left dorsolateral PFC. There was reduced connectivity between the left caudate and ventral PFC and between the left caudate and dorsolateral PFC compared to healthy controls. Additionally, there was hypoactivation of the left caudate in the HIV+ patients. In the control group, there was correlation between caudate activity and executive functioning as shown by performance on neuropsychological testing. Further analysis of the pathways in the HIV+ group involving left caudate showed reduced functional connectivity between the left caudate and globus pallidus (basal ganglia output nucleus). This dysfunction with the basal ganglia and PFC may explain the executive function and semantic event sequencing task impairments noted in HIV+ patients included in this study. [31]

The study by Melrose et al. (2008) also investigated parietal activation. It was found that anterior parietal activation in HIV+ patients was slightly anterior to that in control participants, which follows the idea that HIV causes a reorganization of the attention network leading to cognitive impairments. Additionally, the anterior parietal activity showed a relationship with caudate functioning, which implicates a compensatory mechanism set forth when damage to the fronto-striatal system occurs. [31]

Overall, the study by Melrose et al. (2008) showed that HIV in the brain is associated with cognitive impairments. Damage to the fronto-striatal system may underlie cognitive problems including executive function and sequencing tasks.[ citation needed ]

Another area of impairment due to fronto-striatal dysfunction is in the area of emotion recognition. In a study of HIV+ patients and control adults by Clark et al. (2010), it was shown that HIV patients demonstrate impairments in the recognition of fearful facial expressions. The authors suggested that fronto-striatal abnormalities related to HIV may underlie these impairments. [14]

In identification tasks, administered by Clark et al. (2010), HIV+ patients and control participants were asked to identify different facial emotions and landscapes, with these picture categories matched for image complexity. HIV+ patients did worse than the control group on the facial recognition task but not on landscape identification. In the facial emotion task, fear recognition was significantly worse in the HIV than in the control group. [14]

Neurodevelopmental disorders associated with infection

Mother-to-child transmission during pregnancy is the dominant mode of acquisition of HIV infection in children and has been associated with an increased risk of mortality and developmental delay. Children with AIDS appear to have neurological diseases as a consequence of HIV-1 infection. In HIV-1 infected newborn and children, central nervous system (CNS) is infected with HIV-1 weeks after primary infection, causing neuronal damage and cell death. [32] Although neurological dysfunctions have been associated to HIV infection of the CNS, it is unclear how the pathogenesis of neurological disorders has been established.[ citation needed ]

The main cells infected by HIV-1 in the nervous tissue are the microglia, astrocytes and macrophages, whereas infected neurons have been rarely observed. The susceptibility to HIV-1 infection and replication in neuronal and glial cells is a function of cellular differentiation, and it is more likely in immature precursors than with differentiated cells. Several soluble signals, such as cytokines, have been described to modulate susceptibility and can further contribute in supporting virus latency or virus replication during organ development. In fact, within the developing CNS, cells are under the control of environmental factors that provide instructive signals to neural cell targets. By regulating the survival, differentiation and maintenance of specific functions of neuronal and glial precursors, these extracellular signals can influence many steps of the CNS development and concur in controlling virus-cell interactions in the maturing brain. [33]

In addition to the production of cytokines, HIV-1 infected mononuclear cells and astrocytes can produce a number of soluble mediators, including viral proteins such as gp120 and Tat, that can exert damaging effects on both developing and mature neural tissues. Moreover, molecules such as the platelet activating factor (PAF) and prostaglandins, which are produced upon microglia/macrophages and astrocytes functional interactions, have been reported to mediate cell damage in primary neural cell cultures and neural cell lines with immature phenotype. [34]

Taken together, these observations suggest that the mechanism by which the virus can alter CNS development and induce pathology in the immature brain may depend upon the altered production of soluble bioactive compounds. Several potentially neurotoxic mediators have been identified in different model systems, including inflammatory cytokines, viral proteins and neurotoxic metabolites. Thus, it is likely that a complex interaction of several mediators may alter the function and survival of actively developing and maturing cells, responsible for the neurologic disorders.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Progressive multifocal leukoencephalopathy</span> Viral disease affecting human brains

Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal viral disease characterized by progressive damage (-pathy) or inflammation of the white matter (leuko-) of the brain (-encephalo-) at multiple locations (multifocal). It is caused by the JC virus, which is normally present and kept under control by the immune system. The JC virus is harmless except in cases of weakened immune systems. In general, PML has a mortality rate of 30–50% in the first few months, and those who survive can be left with varying degrees of neurological disabilities.

Myelitis is inflammation of the spinal cord which can disrupt the normal responses from the brain to the rest of the body, and from the rest of the body to the brain. Inflammation in the spinal cord can cause the myelin and axon to be damaged resulting in symptoms such as paralysis and sensory loss. Myelitis is classified to several categories depending on the area or the cause of the lesion; however, any inflammatory attack on the spinal cord is often referred to as transverse myelitis.

<span class="mw-page-title-main">Caudate nucleus</span> Structure of the striatum in the basal ganglia of the brain

The caudate nucleus is one of the structures that make up the corpus striatum, which is part of the basal ganglia in the human brain. Although the caudate nucleus has long been associated with motor processes because of its role in Parkinson's disease, it also plays important roles in nonmotor functions, such as procedural learning, associative learning, and inhibitory control of action. The caudate is also one of the brain structures that compose the reward system, and it functions as part of the cortico-basal ganglia-thalamo-cortical loop.

AIDS-related lymphoma describes lymphomas occurring in patients with acquired immunodeficiency syndrome (AIDS).

<span class="mw-page-title-main">Glial fibrillary acidic protein</span> Type III intermediate filament protein

Glial fibrillary acidic protein (GFAP) is a protein that is encoded by the GFAP gene in humans. It is a type III intermediate filament (IF) protein that is expressed by numerous cell types of the central nervous system (CNS), including astrocytes and ependymal cells during development. GFAP has also been found to be expressed in glomeruli and peritubular fibroblasts taken from rat kidneys, Leydig cells of the testis in both hamsters and humans, human keratinocytes, human osteocytes and chondrocytes and stellate cells of the pancreas and liver in rats.

Cognitive disorders (CDs), also known as neurocognitive disorders (NCDs), are a category of mental health disorders that primarily affect cognitive abilities including learning, memory, perception, and problem-solving. Neurocognitive disorders include delirium, mild neurocognitive disorders, and major neurocognitive disorder. They are defined by deficits in cognitive ability that are acquired, typically represent decline, and may have an underlying brain pathology. The DSM-5 defines six key domains of cognitive function: executive function, learning and memory, perceptual-motor function, language, complex attention, and social cognition.

<span class="mw-page-title-main">Microglia</span> Glial cell located throughout the brain and spinal cord

Microglia are a type of glial cell located throughout the brain and spinal cord of the central nervous system (CNS). Microglia account for about 10–15% of cells found within the brain. As the resident macrophage cells, they act as the first and main form of active immune defense in the CNS. Microglia originate in the yolk sac under tightly regulated molecular conditions. These cells are distributed in large non-overlapping regions throughout the CNS. Microglia are key cells in overall brain maintenance – they are constantly scavenging the CNS for plaques, damaged or unnecessary neurons and synapses, and infectious agents. Since these processes must be efficient to prevent potentially fatal damage, microglia are extremely sensitive to even small pathological changes in the CNS. This sensitivity is achieved in part by the presence of unique potassium channels that respond to even small changes in extracellular potassium. Recent evidence shows that microglia are also key players in the sustainment of normal brain functions under healthy conditions. Microglia also constantly monitor neuronal functions through direct somatic contacts via their microglial processes, and exert neuroprotective effects when needed.

<span class="mw-page-title-main">Viral encephalitis</span> Medical condition

Viral encephalitis is inflammation of the brain parenchyma, called encephalitis, by a virus. The different forms of viral encephalitis are called viral encephalitides. It is the most common type of encephalitis and often occurs with viral meningitis. Encephalitic viruses first cause infection and replicate outside of the central nervous system (CNS), most reaching the CNS through the circulatory system and a minority from nerve endings toward the CNS. Once in the brain, the virus and the host's inflammatory response disrupt neural function, leading to illness and complications, many of which frequently are neurological in nature, such as impaired motor skills and altered behavior.

<span class="mw-page-title-main">Neurosyphilis</span> Infection of the central nervous system in a patient with syphilis

Neurosyphilis is the infection of the central nervous system in a patient with syphilis. In the era of modern antibiotics, the majority of neurosyphilis cases have been reported in HIV-infected patients. Meningitis is the most common neurological presentation in early syphilis. Tertiary syphilis symptoms are exclusively neurosyphilis, though neurosyphilis may occur at any stage of infection.

<span class="mw-page-title-main">Quinolinic acid</span> Dicarboxylic acid with pyridine backbone

Quinolinic acid, also known as pyridine-2,3-dicarboxylic acid, is a dicarboxylic acid with a pyridine backbone. It is a colorless solid. It is the biosynthetic precursor to niacin.

The central nervous system (CNS) controls most of the functions of the body and mind. It comprises the brain, spinal cord and the nerve fibers that branch off to all parts of the body. The CNS viral diseases are caused by viruses that attack the CNS. Existing and emerging viral CNS infections are major sources of human morbidity and mortality.

Peptide T is an HIV entry inhibitor discovered in 1986 by Candace Pert and Michael Ruff, a US neuroscientist and immunologist. Peptide T, and its modified analog Dala1-peptide T-amide (DAPTA), a drug in clinical trials, is a short peptide derived from the HIV envelope protein gp120 which blocks binding and infection of viral strains which use the CCR5 receptor to infect cells.

Neurovirology is an interdisciplinary field which represents a melding of clinical neuroscience, virology, immunology, and molecular biology. The main focus of the field is to study viruses capable of infecting the nervous system. In addition to this, the field studies the use of viruses to trace neuroanatomical pathways, for gene therapy, and to eliminate detrimental populations of neural cells.

<span class="mw-page-title-main">Signs and symptoms of HIV/AIDS</span>

The stages of HIV infection are acute infection, latency, and AIDS. Acute infection lasts for several weeks and may include symptoms such as fever, swollen lymph nodes, inflammation of the throat, rash, muscle pain, malaise, and mouth and esophageal sores. The latency stage involves few or no symptoms and can last anywhere from two weeks to twenty years or more, depending on the individual. AIDS, the final stage of HIV infection, is defined by low CD4+ T cell counts, various opportunistic infections, cancers, and other conditions.

Heart problems are more common in people with HIV/AIDS. Those with left ventricular dysfunction have a median survival of 101 days as compared to 472 days in people with AIDS with healthy hearts. HIV is a major cause of cardiomyopathy. The most common type of HIV induced cardiomyopathy is dilated cardiomyopathy also known as eccentric ventricular hypertrophy which leads to impaired contraction of the ventricles due to volume overload. The annual incidence of HIV associated dilated cardiomyopathy was 15.9/1000 before the introduction of highly active antiretroviral therapy (HAART). However, in 2014, a study found that 17.6% of HIV patients have dilated cardiomyopathy (176/1000) meaning the incidence has greatly increased.

Microglia are the primary immune cells of the central nervous system, similar to peripheral macrophages. They respond to pathogens and injury by changing morphology and migrating to the site of infection/injury, where they destroy pathogens and remove damaged cells.

Georgette D. Kanmogne is a Cameroonian American geneticist and molecular virologist and a full professor and vice chair for resource allocation and faculty development within the Department of Pharmacology and Experimental Neurosciences at the University of Nebraska Medical Center in Omaha, Nebraska. Kanmogne's research program focuses on exploring the pathogenesis of neuroAIDS by deciphering the mechanisms underlying blood brain barrier dysfunction and viral entry into the central nervous system. Her research also addresses the lack of HIV therapies that cross the blood brain barrier (BBB) and has played a critical role in the development of nanoparticles encapsulating HIV-drugs that can cross the BBB to prevent viral-mediated neuron death in the brain. Kanmogne collaborates with clinical and basic researchers across America, Cameroon, and West Africa, spanning disciplines from hematology to psychiatry, to explore how viral genetic diversity is correlated with the neurological impact of HIV.

<span class="mw-page-title-main">Amanda M. Brown</span> American immunologist and microbiologist

Amanda Brown is an American immunologist and microbiologist as well as an associate professor of neurology and neuroscience at Johns Hopkins University School of Medicine in Baltimore, Maryland. Brown is notable for cloning one of the first recombinant HIV viruses and developing a novel method to visualize HIV infected cells using GFP fluorescence.

<span class="mw-page-title-main">Impact of COVID-19 on neurological, psychological and other mental health outcomes</span>

There is increasing evidence suggesting that COVID-19 causes both acute and chronic neurologicalor psychological symptoms. Caregivers of COVID-19 patients also show a higher than average prevalence of mental health concerns. These symptoms result from multiple different factors.

Valerie E. Wojna Muñiz is a Puerto Rican neurologist and professor of neurology at University of Puerto Rico, Medical Sciences Campus.

References

  1. ↑ Lynn, D. Joanne, Newton, Herbert B. and Rae-Grant, Alexander D. eds. 5-Minute Neurology Consult, The. 2nd Edition. Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103 USA: Lippincott Williams & Wilkins, 2012. Books@Ovid. Web. 03 December, 2020.http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=books1&NEWS=N&AN=01626619%2f2nd_Edition%2f2.
  2. 1 2 Gray F, Adle-Biassette H, Chretien F, Lorin de la Grandmaison G, Force G, Keohane C (2001). "Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments". Clinical Neuropathology. 20 (4): 146–55. PMID   11495003.
  3. ↑ "HIV-Associated Dementia - Neurologic Disorders". MSD Manual Professional Edition.
  4. ↑ Adle-Biassette H, Levy Y, Colombel M, Poron F, Natchev S, Keohane C, Gray F (June 1995). "Neuronal apoptosis in HIV infection in adults". Neuropathology and Applied Neurobiology. 21 (3): 218–27. doi:10.1111/j.1365-2990.1995.tb01053.x. PMID   7477730. S2CID   19576463.
  5. ↑ Grant I, Sacktor H, McArthur J (2005). "HIV neurocognitive disorders" (PDF). In Gendelman HE, Grant I, Everall I, Lipton SA, Swindells S (eds.). The Neurology of AIDS (2nd ed.). London, UK: Oxford University Press. pp. 357–373. ISBN   978-0-19-852610-0. Archived from the original (PDF) on 2009-09-23. Retrieved 2006-04-06.
  6. ↑ Satishchandra P, Nalini A, Gourie-Devi M, Khanna N, Santosh V, Ravi V, et al. (January 2000). "Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989-96)". The Indian Journal of Medical Research. 111: 14–23. PMID   10793489.
  7. ↑ Wadia RS, Pujari SN, Kothari S, Udhar M, Kulkarni S, Bhagat S, Nanivadekar A (March 2001). "Neurological manifestations of HIV disease". The Journal of the Association of Physicians of India. 49: 343–8. PMID   11291974.
  8. ↑ Ellis R, Langford D, Masliah E (January 2007). "HIV and antiretroviral therapy in the brain: neuronal injury and repair". Nature Reviews. Neuroscience. 8 (1): 33–44. doi:10.1038/nrn2040. PMID   17180161. S2CID   12936673.
  9. 1 2 González-Scarano F, Martín-García J (January 2005). "The neuropathogenesis of AIDS". Nature Reviews. Immunology. 5 (1): 69–81. doi:10.1038/nri1527. PMID   15630430. S2CID   21564599.
  10. ↑ Castelo JM, Sherman SJ, Courtney MG, Melrose RJ, Stern CE (June 2006). "Altered hippocampal-prefrontal activation in HIV patients during episodic memory encoding". Neurology. 66 (11): 1688–95. doi:10.1212/01.wnl.0000218305.09183.70. PMID   16769942. S2CID   19876874.
  11. ↑ Cysique LA, Maruff P, Brew BJ (December 2004). "Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts". Journal of Neurovirology. 10 (6): 350–7. doi:10.1080/13550280490521078. PMID   15765806. S2CID   9718257.
  12. 1 2 Bogdanova Y, Díaz-Santos M, Cronin-Golomb A (April 2010). "Neurocognitive correlates of alexithymia in asymptomatic individuals with HIV". Neuropsychologia. 48 (5): 1295–304. doi:10.1016/j.neuropsychologia.2009.12.033. PMC   2843804 . PMID   20036267.
  13. ↑ Olesen PJ, Schendan HE, Amick MM, Cronin-Golomb A (December 2007). "HIV infection affects parietal-dependent spatial cognition: evidence from mental rotation and hierarchical pattern perception". Behavioral Neuroscience. 121 (6): 1163–1173. doi:10.1037/0735-7044.121.6.1163. PMID   18085869.
  14. 1 2 3 Clark US, Cohen RA, Westbrook ML, Devlin KN, Tashima KT (November 2010). "Facial emotion recognition impairments in individuals with HIV". Journal of the International Neuropsychological Society. 16 (6): 1127–37. doi:10.1017/S1355617710001037. PMC   3070304 . PMID   20961470.
  15. 1 2 Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. (February 2011). "HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors". Journal of Neurovirology. 17 (1): 3–16. doi:10.1007/s13365-010-0006-1. PMC   3032197 . PMID   21174240.
  16. 1 2 3 Ances BM, Ellis RJ (February 2007). "Dementia and neurocognitive disorders due to HIV-1 infection". Seminars in Neurology. 27 (1): 86–92. doi:10.1055/s-2006-956759. PMID   17226745.
  17. 1 2 Castelo JM, Courtney MG, Melrose RJ, Stern CE (September 2007). "Putamen hypertrophy in nondemented patients with human immunodeficiency virus infection and cognitive compromise". Archives of Neurology. 64 (9): 1275–80. doi: 10.1001/archneur.64.9.1275 . PMID   17846265.
  18. ↑ Fan Y, He JJ (October 2016). "HIV-1 Tat Promotes Lysosomal Exocytosis in Astrocytes and Contributes to Astrocyte-mediated Tat Neurotoxicity". The Journal of Biological Chemistry. 291 (43): 22830–22840. doi: 10.1074/jbc.M116.731836 . PMC   5077215 . PMID   27609518.
  19. ↑ Okamoto S, Kang YJ, Brechtel CW, Siviglia E, Russo R, Clemente A, et al. (August 2007). "HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G1 arrest". Cell Stem Cell. 1 (2): 230–6. doi: 10.1016/j.stem.2007.07.010 . PMID   18371353.
  20. ↑ Thomas S, Mayer L, Sperber K (2009). "Mitochondria influence Fas expression in gp120-induced apoptosis of neuronal cells". The International Journal of Neuroscience. 119 (2): 157–65. doi:10.1080/00207450802335537. PMID   19125371. S2CID   25456692.
  21. ↑ Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Greenberg RN, Berger JR (December 2004). "Neuroimaging correlates of HIV-associated BBB compromise". Journal of Neuroimmunology. 157 (1–2): 140–6. doi:10.1016/j.jneuroim.2004.08.025. PMID   15579291. S2CID   10801232.
  22. ↑ Berger JR, Avison M (September 2004). "The blood brain barrier in HIV infection". Frontiers in Bioscience. 9 (1–3): 2680–5. doi: 10.2741/1427 . PMID   15358591.
  23. ↑ Eugenin EA, Clements JE, Zink MC, Berman JW (June 2011). "Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism". The Journal of Neuroscience. 31 (26): 9456–65. doi:10.1523/jneurosci.1460-11.2011. PMC   3132881 . PMID   21715610.
  24. 1 2 3 Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A, et al. (February 2010). "Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era". Journal of Neurovirology. 16 (1): 25–32. doi:10.3109/13550280903552420. PMC   2995252 . PMID   20113183.
  25. ↑ Nowak MR, Navia B, Harezlak J, Yiannoutsos C, Guttmann C, Singer E, et al. (2014). "Longitudinal Progression of Cortical Atrophy in HIV-Patients on Stable Treatment" (PDF). Conference on Retroviruses and Opportunistic Infections. Boston, MA. Archived from the original (PDF) on 2016-03-04. Retrieved 2018-01-13.
  26. ↑ Cardenas VA, Meyerhoff DJ, Studholme C, Kornak J, Rothlind J, Lampiris H, et al. (July 2009). "Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy". Journal of Neurovirology. 15 (4): 324–33. doi:10.1080/13550280902973960. PMC   2889153 . PMID   19499454.
  27. ↑ Jernigan TL, Archibald SL, Fennema-Notestine C, Taylor MJ, Theilmann RJ, Julaton MD, et al. (June 2011). "Clinical factors related to brain structure in HIV: the CHARTER study". Journal of Neurovirology. 17 (3): 248–57. doi:10.1007/s13365-011-0032-7. PMC   3702821 . PMID   21544705.
  28. ↑ Kaalund SS, Johansen A, Fabricius K, Pakkenberg B (2020). "Untreated Patients Dying With AIDS Have Loss of Neocortical Neurons and Glia Cells". Frontiers in Neuroscience. 13: 1398. doi: 10.3389/fnins.2019.01398 . PMC   6974793 . PMID   32009881.
  29. ↑ Wang X, Foryt P, Ochs R, Chung JH, Wu Y, Parrish T, Ragin AB (2011). "Abnormalities in resting-state functional connectivity in early human immunodeficiency virus infection". Brain Connectivity. 1 (3): 207–17. doi:10.1089/brain.2011.0016. PMC   3621309 . PMID   22433049.
  30. ↑ Grant, I., Atkinson, J. (1995). "Psychiatric aspects of acquired immune deficiency syndrome." (PDF). In Kaplan, H.I. and Sadock, B.J. (ed.). Comprehensive textbook of psychiatry. Vol. 2 (6th ed.). Baltimore, MD: Williams and Wilkins. pp. 1644–1669. ISBN   978-0-683-04532-1. Archived from the original (PDF) on 2009-02-25. Retrieved 2006-04-06.{{cite book}}: CS1 maint: multiple names: authors list (link)
  31. 1 2 Melrose RJ, Tinaz S, Castelo JM, Courtney MG, Stern CE (April 2008). "Compromised fronto-striatal functioning in HIV: an fMRI investigation of semantic event sequencing". Behavioural Brain Research. 188 (2): 337–47. doi:10.1016/j.bbr.2007.11.021. PMID   18242723. S2CID   17016258.
  32. ↑ Calvelli TA, Rubinstein A (2010). "Pediatric HIV infection: a review". Immunodeficiency Reviews. 2 (2): 83–127. PMID   2223063.
  33. ↑ Le Doaré K, Bland R, Newell ML (November 2012). "Neurodevelopment in children born to HIV-infected mothers by infection and treatment status". Pediatrics. 130 (5): e1326-44. doi:10.1542/peds.2012-0405. PMID   23118140. S2CID   8096737.
  34. ↑ Ensoli F, Fiorelli V (2000). "HIV-1 Infection and the Developing CNS". NeuroAids. 3 (1).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.